Indivior director granted 3,722 RSUs

Indivior Pharmaceuticals director receives equity grant.

Rhea-AI Filing Summary

Indivior Pharmaceuticals director receives equity grant. Director Ryan Barbara was granted 3,722 shares of Indivior Pharmaceuticals, Inc. common stock on January 26, 2026 as a stock-based award at a price of $0 per share. After this grant, Barbara beneficially owns 5,685 common shares in total.

The award is in the form of restricted stock units (RSUs), each representing the right to receive one share of common stock. These RSUs vest on the day immediately before the first annual stockholders’ meeting following the grant date, contingent on Barbara’s continued service to the company through that vesting date.

Insider Trade Summary

Grant/Award: 3,722 shares

Grant/Award 1 txn

Insider Ryan Barbara

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,722	$0.00	$0.00

Holdings After Transaction: Common Stock — 5,685 shares (Direct)

Footnotes (1)

1. F1. Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Indivior (INDV) report for Ryan Barbara?

Indivior reported that director Ryan Barbara received a grant of 3,722 restricted stock units on January 26, 2026. Each RSU represents one share of common stock, increasing Barbara’s total beneficial ownership to 5,685 shares following this equity award.

What type of shares did Ryan Barbara receive from Indivior (INDV)?

Ryan Barbara received 3,722 restricted stock units (RSUs) tied to Indivior common stock. Each RSU converts into one share upon vesting, providing stock-based compensation rather than a cash payment at the time of grant.

When do Ryan Barbara’s Indivior (INDV) RSUs vest?

The RSUs granted to Ryan Barbara vest on the day immediately preceding the date of the first annual meeting of Indivior’s stockholders following the grant. Vesting is conditioned on continued service to the company through that vesting date.

How many Indivior (INDV) shares does Ryan Barbara own after this transaction?

Following the January 26, 2026 grant, Ryan Barbara beneficially owns 5,685 shares of Indivior common stock. This total reflects the addition of 3,722 shares from the new restricted stock unit award reported in the Form 4 filing.

Did Ryan Barbara pay cash for the Indivior (INDV) RSU grant?

No cash changed hands for the grant; the 3,722 restricted stock units were awarded at a reported price of $0 per share. This reflects stock-based compensation rather than an open-market purchase of Indivior common stock.

What conditions apply to Ryan Barbara’s Indivior (INDV) RSU award?

The RSU award requires Barbara to remain in service to Indivior through the vesting date. The units vest just before the first annual stockholders’ meeting after the grant, and each vested RSU will deliver one share of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/28/2026 - 04:10 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ryan Barbara

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VA 23235

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		3,722(1)	A	$0	5,685	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.

Remarks:

	/s/ Jordan Saltzberg, Power of Attorney	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.